CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Accumulated Expenses across 12 years of filings, most recently posting $17.0 million for Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 2711.59% year-over-year to $17.0 million; the TTM figure through Jun 2026 stood at $17.0 million (up 2711.59% YoY), while the FY2025 annual figure was $13.1 million, up 25.88% from the prior year.
• Other Accumulated Expenses came in at $17.0 million for Q2 2026 at CRISPR Therapeutics AG, up from $13.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.0 million in Q2 2026 to a low of $461000.0 in Q1 2025.
• Average Other Accumulated Expenses over 5 years is $4.7 million, with a median of $2.4 million recorded in 2022.
• Year-over-year, Other Accumulated Expenses sank 90.44% in 2025 and surged 2744.47% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $1.2 million in 2022, then jumped by 341.67% to $5.1 million in 2023, then surged by 102.63% to $10.4 million in 2024, then gained by 25.88% to $13.1 million in 2025, then grew by 29.51% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $17.0 million in Q2 2026, $13.1 million in Q1 2026, and $13.1 million in Q4 2025.